


Journal Pre-proof

CFTR rescue in W1282X Cystic fibrosis patients-derived intestinal organoids (PDIOs) mediated by translational readthrough-inducing drugs (TRIDs)

Riccardo Perriera, Anabela S. Ramalho, Francois Vermeulen, Emanuele Vitale, Ivana Pibiri, Andrea Pace, Laura Lentini



PII: S2949-7744(25)01511-0

DOI: <https://doi.org/10.1016/j.gimo.2025.103472>

Reference: GIMO 103472

To appear in: *Genetics in Medicine Open*

Received Date: 28 March 2025

Revised Date: 4 November 2025

Accepted Date: 6 November 2025

Please cite this article as: Perriera R, Ramalho AS, Vermeulen F, Vitale E, Pibiri I, Pace A, Lentini L, CFTR rescue in W1282X Cystic fibrosis patients-derived intestinal organoids (PDIOs) mediated by translational readthrough-inducing drugs (TRIDs), *Genetics in Medicine Open* (2025), doi: <https://doi.org/10.1016/j.gimo.2025.103472>.

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: <https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article>. Please also note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.

Authors:

Riccardo Perriera^{1,2}, Anabela S. Ramalho³, Francois Vermeulen^{3,4}, Emanuele Vitale¹, Ivana Pibiri^{1*}, Andrea Pace¹ and Laura Lentini^{1,*}

1. Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, Viale delle Scienze Ed. 16, 90128, University of Palermo, Italy.
2. Department of Research, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione), Via E. Tricomi 5, 90127 Palermo, Italy.
3. KU Leuven, Department of Development and Regeneration, Woman and Child Unit, CF research lab, B-3000 Leuven, Belgium.
4. Department of Pediatrics, Pediatric Pulmonology, UZ Leuven, 3000 Leuven, Belgium.

***Corresponding authors:** Ivana.pibiri@unipa.it; laura.lentini@unipa.it

Orcid: Laura Lentini <https://orcid.org/0000-0002-1355-8252>

Acknowledgments

We thank all the patients who participated in this study.

Funding: We thank the Italian Cystic Fibrosis Research Foundation with the FFC#06/2020 grant to Laura Lentini and Ivana Pibiri. The Belgian Cystic Fibrosis Patient Association, the Path to a Cure Research Grant n°001713G220 from North American Cystic Fibrosis Foundation, and KUL C2 project grant nr. C24M/21/041 to Francois Vermeulen and Anabela Ramalho. The European Union - NextGenerationEU through the Italian Ministry of University and Research under PNRR - M4C2-I1.3 Project PE_00000019 "HEAL ITALIA" to I.P. and L.L. (University of Palermo), CUP B73C22001250006 and PRJ -0863 PRIN2022 to I.P. (University of Palermo) CUP B53D23008390006.

The views and opinions expressed are those of the authors only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the European Commission can be held responsible for them.

Author Details

Author contributions:

Conceptualization: L.L., R.P., A.S.R.; Methodology: R.P., A.S.R., F.V.; Data curation: R.P., A.S.R., I.P., L.L., A.P.; Investigation: R.P., A.S.R., F.V.; Formal analysis: R.P., A.S.R.; Validation: L.L., R.P., A.S.R., I.P.; Resources: L.L., I.P.; Writing – original draft: L.L., R.P., A.S.R., I.P.; Writing – review & editing: L.L., R.P., A.S.R., I.P., F.V., E.V., A.P.; Supervision: L.L., I.P., A.S.R. All authors reviewed and approved the manuscript before submission.

Conflict of Interests

Ivana Pibiri, Laura Lentini, and Andrea Pace have patent licenses to WO2019101709.

Data availability statements

All data described in this study can be obtained from the authors upon request.

Ethics Declaration

This project was approved by the University Hospital Leuven Ethics Review Board (S56329).

All patients and parents gave written informed consent and/or assent.

CFTR rescue in W1282X Cystic fibrosis patients-derived intestinal organoids (PDIOs) mediated by translational readthrough-inducing drugs (TRIDs)

Abstract

Purpose

Pathogenic variants in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene result in dysfunctions of the CFTR protein, leading to Cystic Fibrosis (CF). This genetic disorder is characterized by severe symptoms in the respiratory and digestive systems.

Currently, highly effective CFTR modulator treatments (HEMTs), such as the Elexacaftor–Tezacaftor–Ivacaftor (ETI) combination, may represent the primary therapeutic option for approximately 82% of people with cystic fibrosis (pwCF) who have at least one F508del variant. However, the remaining 18% with rare CFTR variants, including nonsense variants, often lack access to these therapies. Nonsense variants lead to non-functional CFTR proteins and contribute to more severe CF symptoms. Research efforts focus on understanding the effects of these variants on disease severity and response to treatment.

Methods

This study utilizes patient-derived intestinal organoids (PDIOs) to evaluate the recovery of CFTR function in cells with nonsense variants.

Results

Specifically, we tested three translational readthrough-inducing molecules: NV848, NV914, and NV930. Our studies highlighted the positive effect of NV848 on patient organoid swelling, improving CFTR channel function, while NV914 and NV930 didn't induce organoid swelling, similarly to PTC124 treatment.

Conclusion

In conclusion, this study highlights the potential of translational readthrough-inducing molecules to restore CFTR function in cells with nonsense variants. By leveraging patient-derived intestinal organoids, our findings showed that NV848, in combination with ETI and the NMD inhibitor NMDI14, enhances CFTR activity. This contributes to the development of personalized therapies for individuals with rare CFTR variants, addressing a critical unmet need in cystic fibrosis treatment.

Keywords: Cystic fibrosis, CFTR, Translational Readthrough, Intestinal Organoids, Nonsense variants.

Introduction

In vitro research has recently shifted towards more complex systems, surpassing the classic cell-based monolayer models (2D cell cultures) in the study of human biology and diseases. However, it still represents a fundamental step. The evolution of 2D cell cultures to three-dimensional (3D) *in vitro* organoid cultures, which mimic the structure and physiology of several organs *in vivo* and consider the patient's genetic background, is a significant step forward [1, 2]. Organoids are 3D, organ-like structures derived from stem cells, including human induced pluripotent stem cells (hiPSCs) or tissue-derived adult multipotent stem cells. These “miniature organs” exhibit cell differentiation, self-organization, and functionality similar to the corresponding organs in the human body [3]. The organ-like architecture and functionality of organoids offer a unique system for studying organ physiology and pathology [4,5].

One of the key advantages of organoids is their ability to recapitulate the complexity and heterogeneity found in real organs while maintaining the genetic background of the person from which they are derived [6]. Patient-derived intestinal organoids (PDIOs) derived from crypts present in rectal biopsies primarily consist of multipotent adult epithelial stem cells with high expression of CFTR (HGNC:1884), which is reduced after cell differentiation [7]. This *in vitro* 3D model appears as a sphere, with different cellular types constituting its surface, including multipotent and progenitor cells, enterocytes, goblet cells, and Paneth cells interacting in a physical matrix composed of Matrigel (70%). At the same time, the inner part is composed of the lumen of the organoid, which consists of the apical side of the cells, where CFTR is expressed, and the outer part, or basolateral side, of the cells' layer. PDIOs are an innovative *in vitro* system for studying intestinal function, intestinal-related diseases, and drug discovery screening [7].

Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by variants in the cystic fibrosis transmembrane conductance regulator gene (CFTR), which is expressed on the apical side of epithelial cells and functions as an anion-selective channel [8]. The CFTR protein regulates ion transport, specifically Cl⁻ and HCO₃⁻. It maintains water flow through

the plasma membranes of numerous secretory epithelial cells, including those in the airways, intestines, pancreas, kidneys, sweat glands, and male reproductive tract [9]. The absence or alteration of CFTR function leads to dehydration of the mucus layer secreted in several organs' airways and the ducts. This abnormal condition results in nutrient absorption defects, inflammation, duct obstruction, and tissue damage, primarily in the pancreas, lungs, and intestines [10].

Nowadays, highly effective CFTR modulator treatments (HEMTs) like Elexacaftor–lumacaftor–ivacaftor (ETI) may represent the primary therapeutic option for approximately 82% of people with CF (pwCF) who carry at least one F508del variant [NC_000007.14: g.117559593_117559595del NM_000492.4:c.1521_1523del NP_000483.3:p.Phe508del] [11]. However, the remaining 18% have rare CFTR variants that are not eligible for ETI in most countries because of genotype incompatibility, including nonsense variants (corresponding to around 8% of all CFTR alleles) [12].

Nonsense variants introduce a premature termination codon (PTC) instead of a canonical amino acid codon into the CFTR mRNA sequence [13]. The consequence is the production of a truncated and non-functional polypeptide that is signaled for degradation. However, this does not occur in most cases, as the mRNAs harboring the PTCs are prematurely degraded by the nonsense-mediated mRNA decay pathway (NMD), a cellular quality control system [14].

A strategy to restore the correct translation of nonsense-related CFTR mRNAs involves the misreading-promotion of the premature termination codon (PTC) by translational readthrough [15]. The translational readthrough is a mechanism in which a near-cognate transfer RNA (nc-tRNA) is inserted into the A site of the ribosome instead of release factors during the transition of the ribosome on the premature translation termination (PTC). In this case, the resulting protein is full-length and will not be degraded.

Strategies to counteract nonsense variants via NMD inhibition aim to stabilize nonsense-containing mRNAs, allowing for the translation of partially functional proteins. Small-molecule inhibitors, e.g., Amlexanox [16] and NMDI14 [17], targeting NMD components, such as UPF1, are key to this approach and can be combined with readthrough agents to enhance protein synthesis from mutated genes. However, NMD inhibition poses risks, as it may accumulate defective mRNAs, producing truncated or dysfunctional proteins due to its central role in mRNA quality control [18].

Several translational readthrough-inducing drugs (TRIDs) have been identified (e.g., aminoglycoside antibiotics, PTC124, ELX-02) during the last decades. Still, none of these have been able to reach defined outcomes in CF clinical trials [19,20,21].

Recently, three new TRIDs were identified and tested in nonsense-related diseases by 2D *in vitro* systems with promising results. These compounds comprise an oxadiazole core and different substituents for each molecule: NV848, NV914, and NV930 (NV molecules) [22,23]. Considering the limits of the pharmacological approach to suppress nonsense variants, this encouraging evidence must be verified in more complex CF experimental systems to confirm the readthrough efficacy of the NV848, NV914, and NV930.

CFTR is highly expressed in colon tissue, and patient-derived intestinal organoids (PDIOs) are an excellent *in vitro* system for studying the functionality of the channel through specific assays, such as the “swelling assay” [24]. The forskolin-induced swelling (FIS) assay allows the quantification of the CFTR function in PDIOs after treatment with specific compounds to restore the function of the mutated protein channel [25,26]. A positive FIS assay result using CF patients-derived organoids could predict the clinical response to treatment in that patient [27]. This technique's use of patient-specific samples is a significant advantage, particularly for analyzing rare CF genotypes and implementing personalized clinical approaches [28]. PDIOs are among the most reliable *in vitro* models for assessing CFTR protein functionality [29].

This work utilized PDIOs derived from patients carrying CFTR nonsense variants to assess the rescue of CFTR activity following treatment with NV molecules. Two different and prevalent nonsense variants were selected for the study: NC_000007.14:g.117199644C>A NM_000492.4:c.1624G>T NP_000483.3:p.Gly542Ter (G542X) and NC_000007.14:g.117227834G>A NM_000492.4:c.3846G>A NP_000483.3:p.Trp1282Ter (W1282X).

The intestinal organoids were treated with NV848, NV914, or NV930, and the FIS assay was performed to quantify the rescue of CFTR activity. Furthermore, the CFTR modulator compounds Elexacaftor, Tezacaftor, and Ivacaftor were combined with NV molecules to improve the CFTR functionality and protein stability [30,31]. Finally, the NMD pathway was inhibited with NMDI14 to test the possible synergy with the translational readthrough mediated by NV molecules.

Materials and methods

-Compounds

NV848, NV914, and NV930 were prepared as reported in the literature (patents: WO2019101709A1 [IT], US20210002238A1 [US], and EP3713934B1 [EU] [32] or purchased as indicated in Table 1.

-Human intestinal organoids.

Samples of rectal mucosa tissues from pwCF were obtained by suction biopsy during a routine clinic visit at the UZ Leuven University Hospital (Herestraat 49, 3000 Leuven, Belgium). This study was approved by the University Hospital Leuven Ethics Review Board (S56329). All patients/parents gave written informed consent and/or assent. The biopsies were stored in ADF+++ and kept in ice until crypt isolation (see Vonk 2020 for details) [25]. Crypts were isolated from the rectal biopsies and subsequently mixed with 50% matrigel (diluted in cold ADF+++) and plated on 24-well plates; human organoid expansion medium (HM: A83-01 500 nM, SB202190 p38 inhibitor 10 μ M, EGF 50 ng/ml, Nicotinamide 10 mM, N-Acetylcysteine 1.25 mM, B27 supplement 2%, Wnt3A conditioned medium 50%, fcNoggin conditioned medium 10%, Rspo1 conditioned medium 20%, ADF+++ 20%) was added after the solidification of matrigel (0.5 ml per well). The medium was changed every day. Organoids were split by mechanical disruption after 7 days in culture. Two different CFTR genotypes were selected for the study: CFTR^{G542X/G542X} and CFTR^{W1282X/del2,3} NC_000007.14:g.117199644C>A NM_000492.4:c.1624G>T NP_000483.3:p.Gly542Ter (G542X/G542X) and NC_000007.14:g.117498309_117519392del NM_000492.4:c.54-5944_273+10250del (del2,3/W1282X).

-Organoids CFTR activity by FIS assay.

Briefly, organoids (between the 4th and 20th passages) were seeded onto 96-well plates in 4 μ L of 50% Matrigel drops. Each drop, containing 15–60 organoids, was covered with 50 μ L of HM supplemented with the compounds to be incubated for 48 hours. The compounds to be incubated for 24 hours were supplemented the next day.

Green calcein (Invitrogen) was added to stain the organoids (0.02 mg/ μ L) on the day of the FIS assay experiment. Subsequently, forskolin (5 μ M) was added to the organoids to stimulate CFTR activity, which was immediately analyzed by confocal live-cell microscopy (LSM800, 5 $\times$ objective; Zeiss, Oberkochen, Germany). Every 10 minutes (from 0 to 60

minutes, t_0 – t_{60}), a picture was taken of each 96 wells. The total organoid area (xy plane) per well and time point was automatically quantified using Zen Blue analysis software (Zeiss) and normalized to the area at t_0 .

To test the rescue of CFTR function by CFTR modulator compounds, the organoids were pre-incubated for 48 hours with 3 μ M Elexacaftor (VX-445; Selleckchem) and 3 μ M Tezacaftor (VX-661; Selleckchem). Additionally, NV compounds (NV848, NV914, and NV930) were applied at various final concentrations (12, 24, or 48 μ M NV848, NV930, and 12 μ M NV914) for 48 hours, either individually or in combination with VX-445 and VX-661. In a separate experiment, the NMD inhibitor (NMDI14; final concentration of 0.625 μ M; MedChemExpress) was combined with the NV compounds and/or ETI. 3 μ M Ivacaftor (VX-770; Selleckchem) was added as a CFTR potentiator in combination with forskolin. Within each organoid experiment, every test condition was assessed in duplicate. For each organoid genotype, two independent experiments were performed on separate days. Reported values correspond to the average area under the curve (AUC) calculated from plots representing the mean percentage of organoids swelling from t_0 to t_{60} (60 min) and the standard error of the mean from the two independent experiments.

The CFTR function was determined by measuring the organoid swelling after adding forskolin.

-Data analysis.

The experiments were performed at least in duplicate ($n=2$, experimental replicates) and using two technical replicates for each analysis. All data are expressed as mean values $\pm$ standard error of the mean (SEM). The students' t-tests performed statistical analysis and one- and two-way ANOVA when appropriate, using GraphPad Prism software version 7.0.0 for Windows. A probability value (p) of less than 0.05 was regarded as significant and indicated in relevant graphs as one symbol (*) for $p < 0.05$, two symbols (**) for $p < 0.01$, three symbols (***) for $p < 0.001$, and four symbols (****) for $p < 0.0001$.

-Variant Validator

Variants were validated on: <https://variantvalidator.org/>

Results

Intestinal organoids derived from patients carrying CFTR nonsense variants (CFTR^{G542X/G542X} and CFTR^{W1282X/dele2,3}) were used to evaluate CFTR protein activity after

treatment with NV molecules (NV848, NV914, and NV930) and in combination with CFTR modulators.

Data show two different treatment responses. In CFTR^{G542X/G542X} organoids (**fig. 1-A** and **fig.2**), the aminoglycoside ELX-02 (positive control) alone and in combination with ETI show a higher increase in the organoids' area (43.6%) compared to the same treatment in CFTR^{W1282X/dele2,3} organoids (15.3%) (**fig. 1-B** and **fig.3**).

Regarding TRIDs-treated samples, no swelling was detected in CFTR^{G542X/G542X} organoids (**Fig. 1-A**). However, a visible swelling appeared in CFTR^{W1282X/dele2,3} organoids (**Fig. 1-B** and **Fig. 3**) using TRIDs in combination with CFTR modulators. In both genotype samples and all experimental conditions, PTC124 did not induce organoid swelling.

FIS assays were repeated in CFTR^{G542X/G542X} and CFTR^{W1282X/dele2,3} organoids under the same conditions (**fig. 4 A-B** and **fig.5-6**), using the NMD inhibitor NMDI14 (**fig.4 A-B** and **fig.5-6**).

Regarding ELX-02 treatment, data indicate no significant change in AUC (0.85%) between the experiment without NMDI14 (**Fig. 1-A**) and with the addition of the NMD inhibitor (**Fig. 4-A**) alongside ETI treatment. NV molecules treatment did not induce organoid swelling in the presence of NMDI14 (**Fig. 4-A**) in CFTR^{G542X/G542X} organoids.

On the contrary, by inhibiting the NMD pathway through NMDI14 in CFTR^{W1282X/dele2,3} organoids, it is possible to detect an increase in AUC in samples treated with TRIDs and CFTR modulators (**Fig. 4-B** and **Fig. 6**), compared to the FIS assay without NMDI14 (**Fig. 1-B**).

Finally, the percentage of the increasing area during FIS assays in CFTR^{W1282X/dele2,3} organoids evidenced the difference between the CFTR rescue mediated by the most potent NV molecule (NV848) and PTC124 treatment in combination with ETI (**Fig. 7 A-B**). The same result was visible using the NMD inhibitor NMDI14 (**Fig. 7C-D**).

Discussion

The heterogeneity among *CFTR* variants complicates the identification of a unique CF treatment. In alignment with the principles of precision medicine, which emphasize tailored treatments by identifying a targeted therapy for each specific variant, this study provides essential information about CFTR activity rescue in advanced *in vitro* systems related to nonsense variants.

This work aimed to study the effect of the three NV molecules in CF human organoids harboring a CFTR nonsense variant. PDIOs represent an important preclinical *in vitro* system for estimating a molecule's efficacy in rescuing CFTR activity. Our recent work has demonstrated CFTR expression and biochemical maturation in the CF mouse model employed to assess protein rescue [33], thereby supporting its relevance for functional evaluation. Based on this validation, the present study focused on investigating the pharmacological response of CFTR to TRID compounds using functional assays.

NV molecules were tested in two different organoid genotypes (G542X/G542X and W1282X/dele2,3) in combination with CFTR modulators, either alone or in conjunction with ETI, and with or without an NMD pathway inhibitor compound.

In all conditions, NV848, NV914, and NV930 did not work in CFTR^{G542X/G542X} organoids; however, the combination of each NV molecule with CFTR modulators partially restored CFTR activity in CFTR^{W1282X/dele2,3} organoids, especially when using NV848.

Moreover, treatment with NV848, NV914, and NV930, in combination with CFTR modulators and an NMD inhibitor (NMDI14), enhanced the effect of NV molecules in CFTR^{W1282X/dele2,3} organoids.

Interestingly, the commercial readthrough agent PTC124 (Ataluren) was ineffective in CFTR^{W1282X/dele2,3} organoids, unlike the NV848 treatment, which increases channel activity. The PTC124 compound is the only readthrough agent used in clinics to treat other nonsense-related pathologies (e.g., Duchenne muscular dystrophy) [35]. NV848 has been designed by optimization of the lead PTC124; regrettably, PTC124 does not work in the rescue of CFTR protein functionality in nonsense-related organoids test, while results obtained in CF nonsense-related organoids by treatment with NV848 are interesting (**fig. 3**). The three different concentrations of NV848 (12, 24, and 48 μ M) produced similar positive effects as previously observed in FRT CFTR^{W1282X} cells [23], on organoid swelling, contrasting with the limited impact observed with PTC124 treatment (10 μ M; the highest non-toxic concentration), thus highlighting the ability of NV848 to enhance CFTR activity. Notably, the copy of the allele harboring the CFTR exon two-three deletion [NC_000007.14:g.117498309_117519392del NM_000492.4:c.54-5944_273+10250del] does not yield an increase in functional CFTR protein. Neither NV914 (12 μ M; the highest non-toxic concentration) nor NV930 (12, 24, or 48 μ M) induced organoid swelling, similar to the lack of response to PTC124 treatment.

Additionally, the readthrough activity of NV848 synergizes with NMD pathway inhibition, which degrades typically nonsense mRNAs and thereby limits the NV848 effectiveness.

CFTR activity increases when organoids are treated with NV848 and ETI in combination with the NMD inhibitor NMDI14. NMDI14 disrupts the interaction between UPF1 and SMG7, two key protein factors in the NMD pathway [17,36].

The findings obtained in this work added new evidence regarding the study of small molecules capable of restoring the functionality of CFTR in CF nonsense-related *in vitro* systems.

The synergistic effect of the added NMD inhibitor underscores the necessity for an increased mRNA substrate to support readthrough promoter activity, which may explain the lack of efficacy in cases where the nonsense codon occurs too early in the sequence. Furthermore, the observed synergy with CFTR modulators suggests that readthrough likely converts a nonsense variant into a missense variant. This highlights the critical importance of employing robust models to evaluate the functionality of the rescued protein following readthrough treatment [37].

The identification of new effective compounds against CFTR nonsense variants remains one of the most promising avenues in the pharmacological field, especially given the significantly promising compound (ELX-02), which, despite positive *in vitro* 3D results, failed a recent clinical trial (ClinicalTrials.gov Identifier: NCT04135495). NV molecules exhibit a chemical structure distinct from aminoglycoside ELX-02 and have demonstrated good tolerability in mouse animal models [38,39]. In addition, *in vitro* studies on the readthrough side effects of NV molecules on natural termination codons (NTCs) are very promising [40], increasing expectations for these three molecules in treating patients with nonsense variants.

Moreover, it is essential to highlight that the outcome of the preclinical development stage of these prospective drugs would benefit several patients affected by various genetic diseases due to nonsense variants, thereby enlarging the cohort of patients and being particularly helpful, especially for ultrarare diseases still orphaned of a cure.

A limitation of the present study is the lack of comparative data on PDIOs carrying compound heterozygous genotypes (i.e., a PTC and a rescuable missense variant), which would allow a direct comparison between the efficacy of TRIDs combined with CFTR modulators versus CFTR modulators alone. Although such an approach would further clarify the therapeutic contribution of TRID compounds, appropriate patient-derived models were not available at the time of this study. Future work will aim to include PDIOs with broader genotypic representation to address this critical aspect.

In conclusion, the results presented support the potential of NV molecules, particularly NV848, as candidates for further preclinical investigation in the context of CFTR nonsense mutations, while emphasizing the need for additional studies to better define their efficacy and therapeutic relevance.

References

1. Kim J, Koo BK, Knoblich JA. *Human organoids: model systems for human biology and medicine*. Nat Rev Mol Cell Biol. 2020 Oct;21(10):571-584. doi: 10.1038/s41580-020-0259-3. Epub 2020 Jul 7. PMID: 32636524; PMCID: PMC7339799.
2. Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, Fong ELS, Balachander GM, Chen Z, Soragni A, Huch M, Zeng YA, Wang Q, Yu H. *Organoids*. Nat Rev Methods Primers. 2022;2:94. doi: 10.1038/s43586-022-00174-y. Epub 2022 Dec 1. PMID: 37325195; PMCID: PMC10270325.
3. Gu Y, Zhang W, Wu X, Zhang Y, Xu K, Su J. *Organoid assessment technologies*. Clin Transl Med. 2023 Dec;13(12):e1499. doi: 10.1002/ctm2.1499. PMID: 38115706; PMCID: PMC10731122.
4. Taelman J, Diaz M, Guiu J. *Human Intestinal Organoids: Promise and Challenge*. Front Cell Dev Biol. 2022 Mar 11;10:854740. doi: 10.3389/fcell.2022.854740. PMID: 35359445; PMCID: PMC8962662.
5. Fernandes TG. *Organoids as complex (bio)systems*. Front Cell Dev Biol. 2023 Aug 25;11:1268540. doi: 10.3389/fcell.2023.1268540. PMID: 37691827; PMCID: PMC10485618.
6. Calà G, Sina B, De Coppi P, Giobbe GG, Gerli MFM. Primary human organoid models: Current progress and key milestones. Front Bioeng Biotechnol. 2023 Mar 3;11:1058970. doi: 10.3389/fbioe.2023.1058970. PMID: 36959902; PMCID: PMC10029057.
7. Guiu J, Jensen KB. *In Vivo Studies Should Take Priority When Defining Mechanisms of Intestinal Crypt Morphogenesis*. Cell Mol Gastroenterol Hepatol. 2022;13(1):1-3. doi: 10.1016/j.jcmgh.2021.06.028. Epub 2021 Sep 22. PMID: 34562638; PMCID: PMC8600083.
8. Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. *The future of cystic fibrosis care: a global perspective*. Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27. Erratum in: Lancet Respir Med. 2019 Dec;7(12):e40. PMID: 31570318; PMCID: PMC8862661.
9. De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020 May;109(5):893-899. doi: 10.1111/apa.15155. Epub 2020 Jan 22. PMID: 31899933.
10. Gabel ME, Galante GJ, Freedman SD. *Gastrointestinal and Hepatobiliary Disease in Cystic Fibrosis*. Semin Respir Crit Care Med. 2019 Dec;40(6):825-841. doi: 10.1055/s-0039-1697591. Epub 2019 Oct 28. PMID: 31659728.
11. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31. PMID: 31697873; PMCID: PMC7282384.
12. Burgel PR. *Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants*. Lancet Respir Med. 2024 Aug 26: S2213-2600(24)00249-2. doi: 10.1016/S2213-2600(24)00249-2. Epub ahead of print. PMID: 39208837.
13. Pranke I, Golec A, Hinzpeter A, Edelman A, Sermet-Gaudelus I. *Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine*. Front Pharmacol. 2019 Feb 27;10: 121. doi: 10.3389/fphar.2019.00121. PMID: 30873022; PMCID: PMC6400831.

14. Palma M, Lejeune F. *Deciphering the molecular mechanism of stop codon readthrough*. Biol Rev CambPhilos Soc. 2021 Feb;96(1):310-329. doi: 10.1111/brv.12657. Epub 2020 Oct 22. PMID: 33089614.
15. Laselva O, Guerra L, Castellani S, Favia M, Di Gioia S, Conese M. *Small-molecule drugs for cystic fibrosis: Where are we now?* PulmPharmacolTher. 2022 Feb; 72:102098. doi: 10.1016/j.pupt.2021.102098. Epub 2021 Nov 15. PMID: 34793977.
16. Benslimane N, Miressi F, Loret C, Richard L, Nizou A, Pyromali I, Faye PA, Favreau F, Lejeune F, Lia AS. *Amlexanox: Readthrough Induction and Nonsense-Mediated mRNA Decay Inhibition in a Charcot-Marie-Tooth Model of hiPSCs-Derived Neuronal Cells Harboring a Nonsense Variant in GDAP1 Gene*. Pharmaceuticals (Basel). 2023 Jul 21;16(7):1034. doi: 10.3390/ph16071034. PMID: 37513945; PMCID: PMC10385573.
17. Aksit MA, Bowling AD, Evans TA, Joynt AT, Osorio D, Patel S, West N, Merlo C, Sosnay PR, Cutting GR, Sharma N. *Decreased mRNA and protein stability of W1282X limits response to modulator therapy*. J Cyst Fibros. 2019 Sep;18(5):606-613. doi: 10.1016/j.jcf.2019.02.009. Epub 2019 Feb 23. PMID: 30803905; PMCID: PMC6706327.
18. Tan K, Stupack DG, Wilkinson MF. *Nonsense-mediated RNA decay: an emerging modulator of malignancy*. Nat Rev Cancer. 2022 Aug;22(8):437-451. doi: 10.1038/s41568-022-00481-2. Epub 2022 May 27. PMID: 35624152; PMCID: PMC11009036.
19. Prokhorova I, Altman RB, Djumagulov M, Shrestha JP, Urzhumtsev A, Ferguson A, Chang CT, Yusupov M, Blanchard SC, Yusupova G. *Aminoglycoside interactions and impacts on the eukaryotic ribosome*. Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10899-E10908. doi: 10.1073/pnas.1715501114. Epub 2017 Dec 5. PMID: 29208708; PMCID: PMC5754804.
20. Leubitz A, Frydman-Marom A, Sharpe N, van Duzer J, Campbell KCM, Vanhoutte F. *Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Variants, in Healthy Volunteers*. Clin Pharmacol Drug Dev. 2019 Nov;8(8):984-994. doi: 10.1002/cpdd.647. Epub 2019 Jan 16. PMID: 30650260.
21. Huang S, Bhattacharya A, Ghelfi MD, Li H, Fritsch C, Chenoweth DM, Goldman YE, Cooperman BS. *Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination*. Nat Commun. 2022 May 6;13(1):2413. doi: 10.1038/s41467-022-30080-6. PMID: 35523781; PMCID: PMC9076611.
22. Pibiri I., Lentini L., Melfi R, Tutone M, Baldassano S., Ricco Galluzzo P., Di Leonardo A, Pace A, *Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs* Eur J Med Chem 2018 Nov 5;159:126-142. doi: 10.1016/j.ejmech.2018.09.057. Epub 2018 Sep 26.
23. Pibiri I, Melfi R, Tutone M, Di Leonardo A, Pace A, Lentini L. *Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems*. Int J Mol Sci. 2020 Sep 3;21(17):6420. doi: 10.3390/ijms21176420. PMID: 32899265; PMCID: PMC7504161.
24. Ramalho AS, Boon M, Proesmans M, Vermeulen F, Carlon MS, Boeck K. *Assays of CFTR Function In Vitro, Ex Vivo and In Vivo*. Int J Mol Sci. 2022 Jan 27;23(3):1437. doi: 10.3390/ijms23031437. PMID: 35163362; PMCID: PMC8836180.
25. Muilwijk D, de Poel E, van Mourik P, Suen SWF, Vonk AM, Brunsveld JE, Kruisselbrink E, Oppelaar H, Hagemeyer MC, Berkens G, de Winter-de Groot KM, Heida-Michel S, Jans SR, van Panhuis H, van der Eerden MM, van der Meer R, Roukema J, Dompeling E, Weersink EJM, Koppelman GH, Vries R, Zomer-van Ommen DD, Eijkemans MJC, van der Ent CK, Beekman JM. *Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression*. Eur Respir J. 2022 Aug 18;60(2):2100508. doi: 10.1183/13993003.00508-2021. PMID: 35086832; PMCID: PMC9386333.
26. Ramalho AS, Fürstová E, Vonk AM, Ferrante M, Verfaillie C, Dupont L, Boon M, Proesmans M, Beekman JM, Sarouk I, Vazquez Cordero C, Vermeulen F, De Boeck K; Belgian Organoid Project. *Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis*. Eur Respir J. 2021 Jan 5;57(1):1902426. doi: 10.1183/13993003.02426-2019. PMID: 32747394.
27. Berkens G, van Mourik P, Vonk AM, Kruisselbrink E, Dekkers JF, de Winter-de Groot KM, Arets HGM, Marck-van der Wilt REP, Dijkema JS, Vanderschuren MM, Houwen RHJ, Heijerman HGM, van de Graaf EA, Elias SG, Majoor CJ, Koppelman GH, Roukema J, Bakker M, Janssens HM, van der Meer R, Vries RGJ, Clevers HC, de

- Jonge HR, Beekman JM, van der Ent CK. *Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis*. Cell Rep. 2019 Feb 12;26(7):1701-1708.e3. doi: 10.1016/j.celrep.2019.01.068. PMID: 30759382.
28. Van Mourik P, Beekman JM, van der Ent CK. *Intestinal organoids to model cystic fibrosis*. Eur Respir J. 2019 Jul 4;54(1):1802379. doi: 10.1183/13993003.02379-2018. PMID: 31023844.
 29. Bacalhau M, Camargo M, Lopes-Pacheco M. *Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis*. J Pers Med. 2024 Jan 13;14(1):93. doi: 10.3390/jpm14010093. PMID: 38248793; PMCID: PMC10820563
 30. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. *Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele*. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31. PMID: 31697873; PMCID: PMC7282384.
 31. Ridley K, Condren M. *Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy*. J PediatrPharmacolTher. 2020;25(3):192-197. doi: 10.5863/1551-6776-25.3.192. PMID: 32265602; PMCID: PMC7134581.
 32. Pibiri, I., Melfi, R., Tutone, M., Pace, A., Lentini, L. Targeting nonsense: Optimization of 1,2,4-oxadiazole trids to rescue cfr expression and functionality in cystic fibrosis cell model systems International Journal of Molecular Sciences, 2020, 21(17), pp. 1–18, 6420.
 33. Fiduccia, I., Corrao, F., Zizzo, M.G., ... Lentini, L., Pibiri, I. Promoting readthrough of nonsense variants in CF mouse model: Biodistribution and efficacy of NV848 in rescuing CFTR protein expression Molecular Therapy, 2024, 32(12), pp. 4514–4523.
 34. Vonk AM, van Mourik P, Ramalho AS, Silva IAL, Statia M, Kruisselbrink E, Suen SWF, Dekkers JF, Vleggaar FP, Houwen RHJ, Mullenders J, Boj SF, Vries R, Amaral MD, de Boeck K, van der Ent CK, Beekman JM. *Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids*. STAR Protoc. 2020 Jun 3;1(1):100019. doi: 10.1016/j.xpro.2020.100019. PMID: 33111074; PMCID: PMC7580120.
 35. Mercuri E, Osorio AN, Muntoni F, Buccella F, Desguerre I, Kirschner J, Tulinius M, de Resende MBD, Morgenroth LP, Gordish-Dressman H, Johnson S, Kristensen A, Werner C, Trifillis P, Henricson EK, McDonald CM; STRIDE and CINRG DNHS investigators. *Safety and effectiveness of ataluren in patients with nonsense variant DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis*. J Neurol. 2023 Aug;270(8):3896-3913. doi: 10.1007/s00415-023-11687-1. Epub 2023 Apr 28. Erratum in: J Neurol. 2023 Sep;270(9):4583. doi: 10.1007/s00415-023-11864-2. PMID: 37115359; PMCID: PMC10141820.
 36. Mailliot J, Vivoli-Vega M, Schaffitzel C. *No-nonsense: insights into the functional interplay of nonsense-mediated mRNA decay factors*. Biochem J. 2022 May 13;479(9):973-993. doi: 10.1042/BCJ20210556. PMID: 35551602; PMCID: PMC9162471.
 37. McHugh DR, Cotton CU, Hodges CA. *Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Variants*. Int J Mol Sci. 2020 Dec 31;22(1):344. doi: 10.3390/ijms22010344. PMID: 33396210; PMCID: PMC7794695.
 38. Corrao F, Zizzo MG, Tutone M, Melfi R, Fiduccia I, Carollo PS, Leonardo AD, Caldara G, Perriera R, Pace A, Belmonte B, Sammataro S, Pibiri I, Lentini L. *Nonsense codon suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation*. BiomedPharmacother. 2022 Oct 18;156:113886. doi: 10.1016/j.biopha.2022.113886. Epub ahead of print. PMID: 36265311.
 39. De Luca R., Zito A., Saper C.B., Clifford B., Bradford B. *A spatially-resolved transcriptional atlas of the murine dorsal pons at single-cell resolution* Nature Communications, 2024, 15(1) 1966.
 40. Perriera R, Vitale E, Pibiri I, Carollo PS, Ricci D, Corrao F, Fiduccia I, Melfi R, Zizzo MG, Tutone M, Pace A, Lentini L. *Readthrough Approach Using NV Translational Readthrough-Inducing Drugs (TRIDs): A Study of the Possible Off-Target Effects on Natural Termination Codons (NTCs) on TP53 and Housekeeping Gene Expression*. Int J Mol Sci. 2023 Oct 11;24(20):15084. doi: 10.3390/ijms242015084. PMID: 37894764; PMCID: PMC10606485.

Legend to figures

Figure 1: CFTR^{G542X/G542X} (A) and CFTR^{W1282X/dele2,3} (B) organoids were treated for 48 hours with DMSO (negative control), PTC124, ELX-02 (positive control), NV848, NV914, and NV930 at indicated concentrations. CFTR correctors (VX-445 Elexacaftor and VX-661 Tezacaftor; 3 μ M) and CFTR potentiator (VX-770 Ivacaftor; 3 μ M) were added to increase CFTR activity after readthrough rescue. Samples were analyzed and compared to each DMSO negative control (DMSO). Probability value (p): one symbol (*) for $p < 0.05$, two symbols (**) for $p < 0.01$, three symbols (***) for $p < 0.001$, and four symbols (****) for $p < 0.0001$. The experiment was performed in duplicate.

Figure 2: Representative images of statistically significant CFTR^{G542X/G542X} samples and negative controls (DMSO) during the forskolin-induced swelling (FIS) assay. The organoid area was measured at baseline (t0) and after 60 minutes of forskolin (5 μ M) stimulation (t60). Scale bar= 200 μ m.

Figure 3: Representative images of statistically significant CFTR^{W1282X/dele2,3} samples and negative controls (DMSO) during the forskolin inducing swelling (FIS) assay. The organoid area was measured at baseline (t0) and after 60 minutes of forskolin (5 μ M) stimulation (t60). Scale bar= 200 μ m.

Figure 4: CFTR^{G542X/G542X} (A) and CFTR^{W1282X/dele2,3} (B) organoids were treated for 48 hours with DMSO (negative control), PTC124, ELX-02 (positive control), NV848, NV914, and NV930 at indicated concentrations. All samples were treated with NMD inhibitor NMDI14 (0.625 μ M). CFTR correctors (VX-445 Elexacaftor and VX-661 Tezacaftor; 3 μ M) and CFTR potentiator (VX-770 Ivacaftor; 3 μ M) were added to increase CFTR activity after readthrough rescue. Samples were analyzed and compared to each DMSO negative control (DMSO). Probability value (p): one symbol (*) for $p < 0.05$, two symbols (**) for $p < 0.01$, three symbols (***) for $p < 0.001$, and four symbols (****) for $p < 0.0001$. Experiment was performed in duplicate.


Figure 5: Representative images of statistically significant CFTR^{G542X/G542X} samples and negative controls (DMSO) during the forskolin-induced swelling (FIS) assay. All samples were treated with NMDI14 (0.625 μ M). The organoid area was measured at baseline (t0) and after 60 minutes of forskolin (5 μ M) stimulation (t60). Scale bar= 200 μ m.


Figure 6: Representative images of statistically significant CFTR^{W1282X/dele2,3} samples and negative controls (DMSO) during the forskolin-induced swelling (FIS) assay. All samples were treated with NMDI14 (0.625 μ M). Organoid area was measured at baseline (t0) and after 60 minutes of forskolin (5 μ M) stimulation (t60). Scale bar= 200 μ m.


Figure 7: (A-C) Percentage of total CFTR^{W1282X/dele2,3} organoids area (1 hour of FIS), 48 hours after treatment with DMSO (negative control), PTC124, ELX-02 (positive control), and NV848 at indicated concentrations in combination with CFTR modulators (VX-445 Elexacaftor; VX-661 Tezacaftor; VX-770 Ivacaftor; 3 μ M). NMD pathway inhibitor NMDI14 (0.625 μ M) increased TRIDs' efficacy (C). Samples were analyzed and compared to each PTC124 treatment (10 μ M). (B-D) Representative confocal images (calcein staining) of human intestinal organoids (W1282X/dele2,3) during FIS assay (0 min to 60 min). Probability value (p): two symbols (**) for $p < 0.01$ and four symbols (****) for $p < 0.0001$. Scale bar = 100 μ m. The experiment was performed in duplicate.


Compound	Solvent	Stock Concentration	Final Concentration	Manufacturer	Catalog Number
ELX-02	H ₂ O	8mM	80 μ M	MedChem Express (MCE)	HY-114231
PTC124	DMSO	100 mM	10 μ M	MedChem Express (MCE)	HY-14832R
NV848	H ₂ O	100 mM	12–24–48	^a	^a
NV914	DMSO	100 mM	12 μ M	^a	^a
NV930	DMSO	100 mM	12–24–48 μ M	^a	^a
VX-445 (Elexacaftor)	DMSO	10 mM	3 μ M	Selleckchem	S8851
VX-661 (Tezacaftor)	DMSO	20 mM	3 μ M	Selleckchem	S7059
VX-770 (Ivacaftor)	DMSO	20 mM	3 μ M	Selleckchem	S1144
NMDI14	DMSO	6.25 mM	0.625 μ M	MedChem Express (MCE)	HY111374


Table 1: Compounds were dissolved in DMSO (dimethyl sulfoxide, Sigma-Aldrich) or sterile water (H₂O) at the indicated stock concentrations. (^a). All compound stocks were stored at -20°C.











CFTR W1282X/dele2,3

